Essential role of platelet-activating factor receptor in the pathogenesis of Dengue virus infection
- 18 August 2009
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 106 (33), 14138-14143
- https://doi.org/10.1073/pnas.0906467106
Abstract
Severe dengue infection in humans causes a disease characterized by thrombocytopenia, increased levels of cytokines, increased vascular permeability, hemorrhage, and shock. Treatment is supportive. Activation of platelet-activating factor (PAF) receptor (PAFR) on endothelial cells and leukocytes induces increase in vascular permeability, hypotension, and production of cytokines. We hypothesized that activation of PAFR could account for the major systemic manifestations of dengue infection. Inoculation of adult mice with an adapted strain of Dengue virus caused a systemic disease, with several features of the infection in humans. In PAFR(-/-) mice, there was decreased thrombocytopenia, hemoconcentration, decreased systemic levels of cytokines, and delay of lethality, when compared with WT infected mice. Treatment with UK-74,505, an orally active PAFR antagonist, prevented the above-mentioned manifestations, as well as hypotension and increased vascular permeability, and decreased lethality, even when started 5 days after virus inoculation. Similar results were obtained with a distinct PAFR antagonist, PCA-4246. Despite decreased disease manifestation, viral loads were similar (PAFR(-/-)) or lower (PAFR antagonist) than in WT mice. Thus, activation of PAFR plays a major role in the pathogenesis of experimental dengue infection, and its blockade prevents more severe disease manifestation after infection with no increase in systemic viral titers, suggesting that there is no interference in the ability of the murine host to deal with the infection. PAFR antagonists are disease-modifying agents in experimental dengue infection.Keywords
This publication has 36 references indexed in Scilit:
- Natural History of Dengue Virus (DENV)–1 and DENV‐4 Infections: Reanalysis of Classic StudiesThe Journal of Infectious Diseases, 2007
- Murine Model for Dengue Virus-Induced Lethal Disease with IncreasedVascular PermeabilityJournal of Virology, 2006
- Rodent models for the study of therapy against flavivirus infectionsAntiviral Research, 2004
- Interferon-Dependent Immunity Is Essential for Resistance to Primary Dengue Virus Infection in Mice, Whereas T- and B-Cell-Dependent Immunity Are Less CriticalJournal of Virology, 2004
- Role of PAF receptors during intestinal ischemia and reperfusion injury. A comparative study between PAF receptor‐deficient mice and PAF receptor antagonist treatmentBritish Journal of Pharmacology, 2003
- Anti-TNF antibody treatment reduces mortality in experimental dengue virus infectionFEMS Immunology & Medical Microbiology, 2003
- Dengue: an escalating problemBMJ, 2002
- Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acuteGut, 2001
- DECREASED ORGAN FAILURE IN PATIENTS WITH SEVERE SIRS AND SEPTIC SHOCK TREATED WITH THE PLATELET-ACTIVATING FACTOR ANTAGONIST TCV-309: A PROSPECTIVE, MULTICENTER, DOUBLE-BLIND, RANDOMIZED PHASE II TRIALShock, 2000
- LEUKOCYTE-DEPENDENT HISTAMINE RELEASE FROM RABBIT PLATELETSThe Journal of Experimental Medicine, 1972